化合物 PTC-209 HBr|T6178|TargetMol

PTC-209 hydrobromide
1217022-63-3

￥6960 100mg 起订

￥517 2mg 起订

￥849 5mg 起订

上海更新日期：2024-09-30

TargetMol中国（陶术生物）

VIP3年

联系人：邵小姐

手机：4008200310 拨打

邮箱：marketing@tsbiochem.com

产品详情:

中文名称：: 化合物 PTC-209 HBr

英文名称：: PTC-209 hydrobromide

CAS号：: 1217022-63-3

品牌：: TargetMol

产地：: 美国

保存条件：: Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice.

产品类别：: 抑制剂

货号：: T6178

Product Introduction

Bioactivity

名称	PTC-209 hydrobromide
描述	PTC-209 hydrobromide (PTC-209 HBr) is the hydrobromide salt of PTC-209, which is a potent and selective BMI-1 inhibitor with IC50 of 0.5 μM, and results in irreversible reduction of cancer-initiating cells (CICs).
细胞实验	To determine whether pretreatment with the inhibitor affects tumor cell growth, cells are plated with the inhibitor for 4 d in vitro and plated in limiting doses in vitro without adding further inhibitor. Trypan blue exclusion is used to count viable cells. The in vitro sphere-initiating cell frequency is calculated after inhibitor treatment by evaluating the number of wells containing spheres. For the experiments where LDAs are set up following recovery of PTC-209 treated cells, 6-well plates were seeded with 1E6 cells per well and incubated overnight. Cells are subsequently treated for 4 d in triplicate with either DMSO vehicle or PTC-209 (0.01, 0.1, 1 and 10 μM). Drug treatments are washed off and 4 mL fresh suspension medium added to all wells. To assess cell viability following the 4 d treatment window, cells are trypsinized and counted at 0, 24, 72 and 120 h after removal of the drug. Long-lasting effects of the drug treatment on sphere-forming ability are assessed by plating LDAs (50,000, 10,000, 1,000,100, 10 and 1 cell per well) using the cells obtained 120 h after the 4-d drug treatment.(Only for Reference)
激酶实验	Untranslated region-mediated luciferase reporter expression: HEK293 cells are transfected with a GEMS reporter vector that contains the luciferase open-reading frame flanked by and under post-transcriptional control of the BMI-1 5′ and 3′ UTRs. The resulting stable cells (F8) are treated with PTC-209 or vehicle control overnight, and then luciferase reporter activity is determined using Bright-Glo assays. The assays are run in triplicate for each point, and the percentage of inhibition was calculated against vehicle control.
体外活性	PTC-209在人类结直肠癌细胞HCT116和人类纤维肉瘤细胞HT1080中同时抑制UTR介导的报告基因表达和内源性BMI-1表达。PTC-209通过BMI-1依赖的方式减缓结直肠肿瘤细胞生长。此外，PTC-209还通过不可逆的生长抑制作用损害结直肠癌起始细胞(CICs)。[1]
体内活性	PTC-209（60 mg/kg/天，皮下注射）有效抑制了肿瘤组织中BMI-1的产生，并在带有初级人类结肠癌异种移植物、人类结肠癌细胞系LIM1215或HCT116异种移植物的小鼠中停止了已建立肿瘤的生长。PTC-209还在体内减少了功能性结直肠CICs的频率。[1]
存储条件	Powder: -20°C for 3 years \| In solvent: -80°C for 1 year \| Shipping with blue ice.
溶解度	Ethanol : <1 mg/mL H2O : <1 mg/mL DMSO : 93 mg/mL (161.4 mM)
关键字	cells \| HEK293T \| tumor \| breast \| cancer-initiating \| Inhibitor \| PTC-209 Hydrobromide \| PTC209 \| inhibit \| colon \| CICs \| Autophagy \| PTC 209 Hydrobromide \| PTC 209 \| PTC209 Hydrobromide \| lung \| PTC-209 \| anti-myeloma \| PTC209 hydrobromide \| PTC 209 hydrobromide
相关产品	Oxyresveratrol \| Guanidine hydrochloride \| Naringin \| Taurine \| Gefitinib \| Xylitol \| Hydroxychloroquine \| Curcumin \| Stavudine \| Myricetin \| Paeonol \| Sodium 4-phenylbutyrate

PTC-209 HBr|TargetMol

TargetMol Chemicals Inc. 总部位于马萨诸塞州波士顿，致力于为全球生化领域科学家的研究提供专业的产品和服务。TargetMol?品牌的客户群分布于40多个国家和地区，已发展成为全球知名的化合物库和小分子化合物研究供应商。 TargetMol?可提供160多种满足不同需求的化合物库，以及多种类型的生化试剂产品，包括12000多种抑制剂、16000多种天然产物和各类多肽、抗体、生命科学试剂盒等，此外，我们还建设有CADD（计算机辅助药物设计）研究中心、药理实验室、药化合成平台三大技术中心，全方位满足客户的定制需求。凭借我们优质的产品和服务、快速高效的全球供应链和专业的技术支持，我们将有效帮助您缩短研发周期，取得更成功的结果。

成立日期	(12年)
注册资本	566.265100万人民币
员工人数	100-500人
年营业额	￥ 1亿以上
经营模式	贸易,工厂,试剂,定制,服务
主营行业	天然产物,生化试剂,分子生物学,分子砌块,生物技术服务

化合物 PTC-209 HBr相关厂家报价

PTC-209
广州贝尔卡生物科技有限公司
2024-03-04
询价

BMI-1抑制剂(PTC-209)
上海泽叶生物科技有限公司 VIP
2024-11-19
询价

PTC-028
台州市科瑞生物技术有限公司 VIP
2024-09-30
询价

aladdin 阿拉丁 P342998 PTC-209 HBr 1217022-63-3 98%
上海阿拉丁生化科技股份有限公司 VIP
2024-08-16
￥861.90

内容声明